Kapoor Rajan, Nair Ranjith K, Nayan Neelabh, Bhalla Sharad, Singh Jasdeep
Department of Medicine, Command Hospital, Kolkata, India.
Department of Pathology, Command Hospital, Kolkata, India.
SN Compr Clin Med. 2021;3(2):670-674. doi: 10.1007/s42399-021-00790-x. Epub 2021 Feb 10.
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been relentless. We are into the 10th month of the pandemic, and we are still getting surprised every day. Although neutralizing antibodies are generated in response to coronavirus disease-19 (COVID-19), these antibodies do not appear to confer lifelong immunity, as lately there have been reports from various parts of the world of reinfection with the virus, starting from Hong Kong, Belgium, and the USA. The Indian Council of Medical Research (ICMR) has been on-record claiming three cases of reinfection in India. Herein, we report three patients of hematologic malignancy who most probably had reinfection with SARS-CoV-2, after complete documented recovery from first infection. All three patients were immunocompromised owing to their primary hematologic malignancy coupled with ongoing therapy, and the second infection was documented to be severe in all the three cases from the first episode.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染一直持续不断。我们正处于这场大流行的第10个月,每天仍会感到惊讶。尽管针对冠状病毒病19(COVID-19)会产生中和抗体,但这些抗体似乎并不能提供终身免疫,因为最近从香港、比利时和美国等地开始,世界各地都有再次感染该病毒的报道。印度医学研究理事会(ICMR)已记录在案,称印度有3例再次感染病例。在此,我们报告3例血液系统恶性肿瘤患者,他们在首次感染有完整记录的康复后,很可能再次感染了SARS-CoV-2。所有3例患者由于原发性血液系统恶性肿瘤及正在进行的治疗而免疫功能低下,且在所有3例中,第二次感染从首次发作起就被记录为严重感染。